CRISPR Therapeutics AG [CRSP] stock prices are up 7.24% to $56.12 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRSP shares have gain 11.19% over the last week, with a monthly amount glided 36.88%, and seem to be holding up well over a long-time horizon.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
On 11, January 2023, CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference. In a post published today on Yahoo Finance, CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on October 11, 2022, when Morgan Stanley initiated its Underweight rating and assigned the stock a price target of $37. Previously, Barclays downgraded its rating to Equal Weight on August 09, 2022, and dropped its price target to $88. On June 23, 2022, downgrade downgraded it’s rating to In-line and revised its price target to $60 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $98 on June 17, 2022. Credit Suisse initiated its recommendation with a Neutral and recommended $78 as its price target on April 28, 2022. In a note dated October 19, 2021, SVB Leerink initiated an Outperform rating and iterated a target price of $126 on this stock.
The stock price of CRISPR Therapeutics AG [CRSP] has been fluctuating between $38.94 and $86.95 over the past year. Currently, Wall Street analysts expect the stock to reach $98.00 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $56.12 at the most recent close of the market. An investor can expect a potential return of 74.63% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
The most recent quarter, CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 94.0 million, representing a drop of -87.50%. Gross Margin for this corporation currently stands at +98.04% with Operating Margin at +40.82%, Pretax Margin comes in at +41.48%, and Net Margin reading is +41.28%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.09 points at the first support level, and at 50.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.83, and for the 2nd resistance point, it is at 61.53.
CRISPR Therapeutics AG [CRSP] reported earnings per share of -$2.4 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$2.23/share, meaning a difference of -$0.17 and a surprise factor of -7.60%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$2.32 per share as compared to estimates of -$1.94 per share, a difference of -$0.38 representing a surprise of -19.60%.
Ratios To Look Out For
It’s worth pointing out that CRISPR Therapeutics AG [NASDAQ:CRSP]’s Current Ratio is 12.80. In addition, the Quick Ratio stands at 20.17 and the Cash Ratio stands at 19.85. Considering the valuation of this stock, the price to sales ratio is 6.66, the price to book ratio is 2.43.
Transactions by insiders
In the past 3 months, 4 insiders have purchased 129,900 shares, and 5 have sold 47,635 shares. Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Jan 27 when 25000.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Dec 28 to sell 25000.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 25000.0 shares on Nov 28.